0001104659-22-047468.txt : 20220419
0001104659-22-047468.hdr.sgml : 20220419
20220419194856
ACCESSION NUMBER: 0001104659-22-047468
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220418
FILED AS OF DATE: 20220419
DATE AS OF CHANGE: 20220419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ali Asif
CENTRAL INDEX KEY: 0001921163
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37852
FILM NUMBER: 22836048
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc
CENTRAL INDEX KEY: 0001377121
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980505495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
BUSINESS PHONE: (510) 474-0170
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Therapeutics Inc
DATE OF NAME CHANGE: 20130605
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Inc
DATE OF NAME CHANGE: 20061002
4
1
tm2212815-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-04-18
0
0001377121
Protagonist Therapeutics, Inc
PTGX
0001921163
Ali Asif
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
0
1
0
0
Chief Financial Officer
Common Stock
2022-04-18
4
A
0
13750
0.00
A
13750
D
Stock Option (right to buy)
19.19
2022-04-18
4
A
0
82500
0.00
A
2032-04-18
Common Stock
82500
82500
D
Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on April 18, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer.
The stock option represents a right to purchase a total of 82,500 shares of the Issuer's common stock, one quarter of which will vest on April 18, 2023, with the remaining three quarters vesting in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
/s/ Asif Ali
2022-04-19